<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7021315\results\search\tropicalVirus\results.xml">
  <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Microbiology :"/>
  <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences : Pathology and"/>
  <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Organisms :"/>
  <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Physiology :"/>
  <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
  <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
  <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
  <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Immunology :"/>
  <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Zika" post="Fever : Medicine and Health Sciences : Infectious Diseases"/>
  <result pre="Proteins: Serum Proteins Impact of flavivirus vaccine-induced immunity on primary" exact="Zika" post="virus antibody response in humans Impact of prior flavivirus"/>
  <result pre="antibody response in humans Impact of prior flavivirus immunity on" exact="Zika" post="virus antibody response http://orcid.org/0000-0002-0222-9832MalafaStefanFormal analysisInvestigationMethodologyValidationVisualizationWriting – original draftWriting –"/>
  <result pre="provided the original author and source are credited.pntd.0008034.pdf Abstract Background" exact="Zika" post="virus has recently spread to South- and Central America,"/>
  <result pre="Since pre-existing cross-reactive immunity can potentially modulate antibody responses to" exact="Zika" post="virus infection and may affect the outcome of disease,"/>
  <result pre="virus-neutralizing and infection-enhancing activities of antibodies induced by a primary" exact="Zika" post="virus infection in flavivirus-naïve as well as yellow fever-"/>
  <result pre="and/or tick-borne encephalitis-vaccinated individuals. Methodology Antibodies in sera from convalescent" exact="Zika" post="patients with and without vaccine-induced immunity were assessed by"/>
  <result pre="without vaccine-induced immunity were assessed by ELISA with respect to" exact="Zika" post="virus-specificity and flavivirus cross-reactivity. Functional analyses included virus neutralization"/>
  <result pre="had a strong influence on the antibody response in primary" exact="Zika" post="virus infections, resulting in higher titers of broadly flavivirus"/>
  <result pre="of broadly flavivirus cross-reactive antibodies and slightly lower levels of" exact="Zika" post="virus-specific IgM. Antibody-dependent enhancement (ADE) of Zika virus was"/>
  <result pre="lower levels of Zika virus-specific IgM. Antibody-dependent enhancement (ADE) of" exact="Zika" post="virus was mediated by sub-neutralizing concentrations of specific IgG"/>
  <result pre="both neutralize and enhance infection of dengue virus but not" exact="Zika" post="virus, indicating a different exposure of conserved sequence elements"/>
  <result pre="In addition, our results highlight structural differences between strains of" exact="Zika" post="and dengue viruses that are used for analyzing infection-enhancement"/>
  <result pre="disease and vaccination efficacy. Author summary The explosive spread of" exact="Zika" post="virus, a flavivirus, to South- and Central America underscores"/>
  <result pre="America underscores the potential threat of newly emerging arthropod-borne viruses." exact="Zika" post="virus infection can cause congenital birth defects and neurological"/>
  <result pre="infections with other flaviviruses (e.g. dengue virus, which co-circulates in" exact="Zika" post="outbreak regions) or vaccinations (e.g. against yellow fever or"/>
  <result pre="of serum samples from flavivirus-naïve and vaccinated individuals after primary" exact="Zika" post="virus infections. Prior immunity led to a strong booster"/>
  <result pre="a strong booster of cross-reactive antibodies that did not neutralize" exact="Zika" post="virus. Importantly, we could also show that newly formed"/>
  <result pre="and its Supporting Information files. Introduction Epidemics of infections with" exact="Zika" post="virus, a mosquito-borne flavivirus, first emerged in Pacific islands"/>
  <result pre="in newborns after infection of pregnant women became apparent [3]." exact="Zika" post="virus is a close relative of other important human"/>
  <result pre="pathogenic flaviviruses like dengue (DEN) virus, yellow fever (YF) virus," exact="West Nile" post="(WN) virus, Japanese encephalitis virus, tick-borne encephalitis (TBE) virus"/>
  <result pre="tropical and sub-tropical regions around the world or dengue and" exact="Zika" post="viruses in South and Central America or Southeast Asia"/>
  <result pre="analyzed the antibody response in groups of individuals with recent" exact="Zika" post="virus infections that were either flavivirus-naïve or had previously"/>
  <result pre="such cryptic antigenic sites [19, 21]. Fig 1 Structure of" exact="Zika" post="virus and antigenic relationships of flaviviruses. (A) Zika virus"/>
  <result pre="Structure of Zika virus and antigenic relationships of flaviviruses. (A)" exact="Zika" post="virus particle (PDB: 6CO8, [22]). (B) Distance relationships between"/>
  <result pre="on amino acid sequence differences. (C) Ribbon diagram of the" exact="Zika" post="virus E dimer (side view) and (D) surface representation"/>
  <result pre="E dimer (side view) and (D) surface representation of the" exact="Zika" post="virus E dimer (top view). Color code: domain I"/>
  <result pre="for tick-borne encephalitis virus, AY640589 for yellow fever virus, DQ211652for" exact="West Nile" post="virus, D90194 for Japanese encephalitis virus, KJ776791 for Zika"/>
  <result pre="West Nile virus, D90194 for Japanese encephalitis virus, KJ776791 for" exact="Zika" post="virus, AF226687 for dengue 1 virus, DQ863638 for dengue"/>
  <result pre="vaccine-induced immunity on IgM and IgG profiles after recent primary" exact="Zika" post="virus infection. For this purpose, we analyzed samples from"/>
  <result pre="Zika virus infection. For this purpose, we analyzed samples from" exact="Zika" post="patients, who were either flavivirus naïve or had previously"/>
  <result pre="YF. We demonstrate that virus-specific IgM antibodies contribute substantially to" exact="Zika" post="virus neutralization in the early phase of infection and"/>
  <result pre="an important role in the prevention of IgG-mediated enhancement of" exact="Zika" post="virus infection of Fcγ receptor-positive cells. Importantly, the formation"/>
  <result pre="IgG antibodies, which caused ADE of dengue but not of" exact="Zika" post="virus infection in vitro. Our findings contribute to the"/>
  <result pre="of vaccines. Methods Ethics statement Human serum samples from 62" exact="Zika" post="patients were sent to the Center for Virology of"/>
  <result pre="from 62 patients who were diagnosed with an acute symptomatic" exact="Zika" post="virus infection after returning to Europe from Zika-endemic areas."/>
  <result pre="infection after returning to Europe from Zika-endemic areas. They developed" exact="Zika" post="virus-specific IgM and neutralizing antibodies, and 30 patients were"/>
  <result pre="Zika virus-specific IgM and neutralizing antibodies, and 30 patients were" exact="Zika" post="PCR positive (23 negative, 9 not tested). Samples from"/>
  <result pre="negative, 9 not tested). Samples from only two of these" exact="Zika" post="patients exhibited a low degree of broad flavivirus cross-reactivity"/>
  <result pre="strain NCBI Nucleotide NCBI Protein amino acids of E reference" exact="Zika" post="virus H/PF/2013 KJ776791 AHZ13508.1 1–408 [44] Rio Bravo virus"/>
  <result pre="1–393 [45] TBE virus Neudörfl U27495 AAA86870.1 1–400 [40, 43]" exact="Dengue" post="virus 2 16681 NC_001474.2 NP_056776.2 1–399 this study WN"/>
  <result pre="Technologies Inc.). Determination of the oligomeric state of the recombinant" exact="Zika" post="E protein Zika and WN virus E proteins were"/>
  <result pre="of the oligomeric state of the recombinant Zika E protein" exact="Zika" post="and WN virus E proteins were analyzed by rate"/>
  <result pre="as described previously [43, 47]. The monomer control for the" exact="Zika" post="virus E protein was prepared by incubation with 1%"/>
  <result pre="corresponding purified protein as a standard. Size-exclusion chromatography of the" exact="Zika" post="and WN virus E proteins was carried out with"/>
  <result pre="each ELISA plate. This control serum was obtained from a" exact="Zika" post="patient with YF and TBE pre-immunity and yielded similar"/>
  <result pre="(C8 and C10 –[44, 50], giving a positive reaction in" exact="Zika" post="and dengue ELISAs), the dengue-specific mab 4E11 [51], and"/>
  <result pre="in the TBE ELISA only). For cut-off determination of the" exact="Zika" post="and RB assays, we used 32 diagnostic serum samples"/>
  <result pre="negative controls at a 1:100 dilution plus 3 standard deviations." exact="Zika" post="IgG avidity ELISA Relative avidities of polyclonal serum samples"/>
  <result pre="ELISA Relative avidities of polyclonal serum samples were analyzed with" exact="Zika" post="virus E protein in the flavivirus IgG ELISA described"/>
  <result pre="was controlled using serum samples obtained early and late after" exact="Zika" post="virus infection (S2 Fig). Zika and RB IgM ELISA"/>
  <result pre="obtained early and late after Zika virus infection (S2 Fig)." exact="Zika" post="and RB IgM ELISA MaxiSorp microtiter plates (Nunc) were"/>
  <result pre="and Strep-Tactin-labeled HRP (IBA GmbH, Göttingen, Germany). For the quantitative" exact="Zika" post="IgM ELISA, a Zika virus post-infection serum sample (TBE-pre-vaccinated"/>
  <result pre="GmbH, Göttingen, Germany). For the quantitative Zika IgM ELISA, a" exact="Zika" post="virus post-infection serum sample (TBE-pre-vaccinated patient) was included as"/>
  <result pre="TBE and dengue neutralization tests (NTs) NTs were performed with" exact="Zika" post="virus strain H/PF/2013 (European virus archive), dengue virus serotype"/>
  <result pre="prM [56, 57] TBE virus IC3 TBE E DI [58]" exact="Zika" post="virus A1 flavivirus FL-specific [48] The assays were validated"/>
  <result pre="with neutralizing mabs specific for the different viruses, as follows:" exact="Zika" post="and dengue viruses were neutralized by the EDE-specific mabs"/>
  <result pre="corresponding to their activities reported in the literature [44, 50]." exact="Dengue" post="viruses were also tested with the dengue-specific mab 4E11"/>
  <result pre="Serial dilutions of heat-inactivated serum samples were pre-incubated with either" exact="Zika" post="virus or dengue virus serotype 2 (5,000–10,000 viral RNA"/>
  <result pre="and probes used in this study targeted the NS5 gene:" exact="Zika" post="virus: forward primer: ACAAGGGGAATTTGGAAAGGC; reverse primer: GAATCCAAGGGCTTCGAACTC; probe: FAM-AGCCGCGCCATCTGGTATATGTGG-TAMRA."/>
  <result pre="Zika virus: forward primer: ACAAGGGGAATTTGGAAAGGC; reverse primer: GAATCCAAGGGCTTCGAACTC; probe: FAM-AGCCGCGCCATCTGGTATATGTGG-TAMRA." exact="Dengue" post="virus 2: forward primer: CAGATGGAGGGAGAAGGAGTC; reverse primer: CGCCCTACTCTTGCTAACCA; probe:"/>
  <result pre="Scientific). A plasmid encoding part of the NS5 gene of" exact="Zika" post="virus or dengue virus 2 (synthesized by GeneArt/Thermo Fisher"/>
  <result pre="in the literature [61], and we observed no enhancement of" exact="Zika" post="virus under these conditions. As a negative control for"/>
  <result pre="the WN virus E protein [62]. Depletion of antibodies with" exact="Zika" post="or RB virus E protein For the depletion of"/>
  <result pre="Zika or RB virus E protein For the depletion of" exact="Zika" post="virus-specific or flavivirus broadly cross-reactive antibodies, 200 μg Zika"/>
  <result pre="of Zika virus-specific or flavivirus broadly cross-reactive antibodies, 200 μg" exact="Zika" post="or RB virus E protein were bound to Strep-Tactin"/>
  <result pre="and incubated for 10 min at RT. To deplete completely" exact="Zika" post="or RB virus-reactive antibodies a minimum of eight rounds"/>
  <result pre="verified by the flavivirus IgG ELISA (described above), using the" exact="Zika" post="virus E protein, and the presence of IgM in"/>
  <result pre="presence of IgM in the final eluate was confirmed by" exact="Zika" post="IgM ELISA (described above). IgM depletion 1 ml anti-IgM"/>
  <result pre="supernatant was subjected to control ELISAs. Depletion was verified by" exact="Zika" post="IgM ELISA (described above), and the presence of IgG"/>
  <result pre="confirmed by the flavivirus IgG ELISA (described above), using the" exact="Zika" post="virus E protein. Statistics Antibody titers that were less"/>
  <result pre="with urea as offset applying a GLM. Fold enhancement of" exact="Zika" post="and dengue virus infectivity between depleted and mock-depleted sera"/>
  <result pre="area under the log-dilution-log-fold-enhancement curves using GLM. Fold enhancement of" exact="Zika" post="virus between depleted and mock-depleted sera (using a single"/>
  <result pre="flavivirus immunity on the patterns of antibody responses in primary" exact="Zika" post="virus infections, we analyzed serum samples from laboratory-confirmed Zika"/>
  <result pre="primary Zika virus infections, we analyzed serum samples from laboratory-confirmed" exact="Zika" post="patients (travelers returning from Zika-endemic regions) with and without"/>
  <result pre="were randomly received for diagnostic purposes from travelers returning with" exact="Zika" post="virus infections, the groups were relatively heterogeneous with respect"/>
  <result pre="not been documented for the diagnostic samples used. 10.1371/journal.pntd.0008034.t003Table 3" exact="Zika" post="patients. flavivirus pre-immunity patientsn median age in years (range)"/>
  <result pre="multiple samples were available. Our analyses included the quantification of" exact="Zika" post="virus-specific and flavivirus cross-reactive IgM and IgG antibodies in"/>
  <result pre="as well as the determination of in vitro ADE of" exact="Zika" post="and dengue virus infections. Because these experiments required relatively"/>
  <result pre="pools. 10.1371/journal.pntd.0008034.t004Table 4 Serum samples from flavivirus naïve and pre-immune" exact="Zika" post="patients used for pools. flavivirus pre-immunity patientsna median age"/>
  <result pre="per patient was included in the pools. Characterization of the" exact="Zika" post="virus E dimer For the analysis of Zika virus-specific"/>
  <result pre="of the Zika virus E dimer For the analysis of" exact="Zika" post="virus-specific antibodies, we used a recombinant Zika virus E"/>
  <result pre="the analysis of Zika virus-specific antibodies, we used a recombinant" exact="Zika" post="virus E protein with a C-terminal strep-tag and lacking"/>
  <result pre="of E (E-dimer dependent epitope, EDE) [44]. In addition, the" exact="Zika" post="virus E protein was shown to have high affinity"/>
  <result pre="by Biolayer Interferometry [44]. The stable dimeric structure of the" exact="Zika" post="virus E protein in solution was verified by sedimentation"/>
  <result pre="crystals [54, 63, 64]. In addition, we analyzed whether our" exact="Zika" post="E dimer is recognized by the human EDE-specific mabs"/>
  <result pre="analyze the functional activity of polyclonal antibodies detected with the" exact="Zika" post="virus E dimer, we depleted three of the four"/>
  <result pre="Table 4 as well as four serum samples from individual" exact="Zika" post="patients (1 serum from each pool) with this protein."/>
  <result pre="more of NT activity was removed, indicating that the dimeric" exact="Zika" post="antigen allows the measurement of most of the functionally"/>
  <result pre="pools and individual sera (see Table 4) were tested in" exact="Zika" post="and Rio Bravo (RB) IgM as well as IgG"/>
  <result pre="Rio Bravo (RB) IgM as well as IgG ELISA, and" exact="Zika" post="NT. In all cases, the mean values of the"/>
  <result pre="the naïve and pre-immune pools would be even more pronounced." exact="Zika" post="IgG avidity could only be performed with the pools"/>
  <result pre="of individual sera. All four groups produced high amounts of" exact="Zika" post="virus-specific IgM antibodies, which were slightly higher in the"/>
  <result pre="flaviviruses (Fig 1B). In contrast to the IgM results, the" exact="Zika" post="virus-specific IgG response was significantly higher in all pre-vaccinated"/>
  <result pre="suggested by the higher relative avidities of these groups in" exact="Zika" post="IgG ELISA (Fig 2E), this pattern is consistent with"/>
  <result pre="booster response of IgG in the pre-vaccinated individuals. In the" exact="Zika" post="neutralization test (NT), however, no differences were found among"/>
  <result pre="cross-reactive antibodies did not contribute significantly to the neutralization of" exact="Zika" post="virus. Fig 2 Zika virus-specific and broadly cross-reactive antibody"/>
  <result pre="contribute significantly to the neutralization of Zika virus. Fig 2" exact="Zika" post="virus-specific and broadly cross-reactive antibody titers of four serum"/>
  <result pre="of individual sera are shown as red open circles. (A)" exact="Zika" post="virus IgM ELISA units, (B) Rio Bravo virus IgM"/>
  <result pre="Rio Bravo virus IgM ELISA absorbance values (cross-reactive antibodies), (C)" exact="Zika" post="virus IgG ELISA titers, (D) Rio Bravo virus IgG"/>
  <result pre="Rio Bravo virus IgG ELISA titers (cross-reactive antibodies), (E) relative" exact="Zika" post="virus IgG avidities (%), (F) Zika virus NT50 titers."/>
  <result pre="(cross-reactive antibodies), (E) relative Zika virus IgG avidities (%), (F)" exact="Zika" post="virus NT50 titers. The cut-off is indicated by a"/>
  <result pre="0.05; **, p &amp;lt; 0.01; ***, p &amp;lt; 0.001. ZIKV," exact="Zika" post="virus; RBV, Rio Bravo virus; naïve, flavivirus naïve serum"/>
  <result pre="and tick-borne encephalitis pre-vaccinated serum pool. Role of IgM in" exact="Zika" post="virus NT and ADE To obtain information about the"/>
  <result pre="GLM and Wald’s test as described in Methods. Fig 3" exact="Zika" post="virus neutralization NT50 titers by IgM after IgG depletion"/>
  <result pre="contrasts); *, p &amp;lt; 0.05; **, p &amp;lt; 0.01. ZIKV," exact="Zika" post="virus; naïve, flavivirus naïve serum pool; YF+, yellow fever"/>
  <result pre="extent the presence of neutralizing IgM antibodies could affect IgG-mediated" exact="Zika" post="virus ADE of infection. For this purpose, we determined"/>
  <result pre="Effect of IgM depletion from serum pools on ADE of" exact="Zika" post="virus infection. Serum pools were depleted with IgM agarose"/>
  <result pre="described in Methods. Fcγ receptor-positive K562 cells were infected with" exact="Zika" post="virus in the presence of serially diluted (A) flavivirus-naïve"/>
  <result pre="line indicates no enhancement of infection. Comparison of fold-enhancement of" exact="Zika" post="virus infection in the presence of depleted and mock-depleted"/>
  <result pre="described in Methods. p-values are indicated in the graphs. ZIKV," exact="Zika" post="virus; naïve, flavivirus naïve serum pool; YF+, yellow fever"/>
  <result pre="5 Effect of IgM and IgG depletion on ADE of" exact="Zika" post="virus infection. The four serum pools were depleted from"/>
  <result pre="described in Methods. Fcγ receptor-positive K562 cells were infected with" exact="Zika" post="virus in the presence of a 1:1000 dilution of"/>
  <result pre="pre-vaccinated serum pool. Role of broadly flavivirus cross-reactive antibodies in" exact="Zika" post="virus NT and ADE Since the pre-immune groups had"/>
  <result pre="flavivirus cross-reactive antibodies (Fig 2D), we quantified their contribution to" exact="Zika" post="virus neutralization and enhancement by depletion of these antibodies"/>
  <result pre="this procedure (S8 Fig). Analysis of the depleted samples in" exact="Zika" post="IgG ELISA (Fig 6A) revealed that more than 60%"/>
  <result pre="6A) revealed that more than 60% of IgG reactivity were" exact="Zika" post="virus-specific in the naïve group, contrasting to only 5.8"/>
  <result pre="the naïve group. The data show that the newly synthesized" exact="Zika" post="virus-specific antibodies (i.e. those not removed by RB depletion)"/>
  <result pre="and 0.998). Depletion of cross-reactive antibodies had no influence on" exact="Zika" post="virus neutralization (Fig 6C)—consistent with the data displayed in"/>
  <result pre="displayed in Fig 2 - and did not significantly affect" exact="Zika" post="virus ADE (Fig 7A–7D). Fig 6 Effect of depletion"/>
  <result pre="antibodies from serum pools with Rio Bravo virus E on" exact="Zika" post="virus antibody titers. (A) Zika virus IgG ELISA titers,"/>
  <result pre="Rio Bravo virus E on Zika virus antibody titers. (A)" exact="Zika" post="virus IgG ELISA titers, (B) relative avidity of Zika"/>
  <result pre="(A) Zika virus IgG ELISA titers, (B) relative avidity of" exact="Zika" post="virus-specific IgG, and (C) Zika virus NT50 titers. Colored"/>
  <result pre="titers, (B) relative avidity of Zika virus-specific IgG, and (C)" exact="Zika" post="virus NT50 titers. Colored columns: mock depletion, empty columns:"/>
  <result pre="0.05; **, p &amp;lt; 0.01; ***, p &amp;lt; 0.001. ZIKV," exact="Zika" post="virus; mock dep, IgM and mock-depleted serum pool; RB"/>
  <result pre="serum pools with Rio Bravo virus E on ADE of" exact="Zika" post="virus infection. Fcγ receptor-positive K562 cells were infected with"/>
  <result pre="Zika virus infection. Fcγ receptor-positive K562 cells were infected with" exact="Zika" post="virus in the presence of serially diluted (A) flavivirus-naïve"/>
  <result pre="line indicates no enhancement of infection. Comparison of fold-enhancement of" exact="Zika" post="virus infection in the presence of depleted and mock-depleted"/>
  <result pre="described in Methods. p-values are indicated in the graphs. ZIKV," exact="Zika" post="virus; mock dep, IgM and mock-depleted serum pool; RB"/>
  <result pre="are more accessible in infectious dengue than in TBE and" exact="Zika" post="viruses (compare Fig 6C). This conclusion is also confirmed"/>
  <result pre="TBE and dengue virus neutralization. (A) TBE virus NT. (B)" exact="Dengue" post="virus NT. IgG-containing serum pools were further depleted with"/>
  <result pre="therefore also compared individual serum samples from naïve and pre-immune" exact="Zika" post="patients (Table 3), for which sufficient volumes were available,"/>
  <result pre="patients (Table 3), for which sufficient volumes were available, in" exact="Zika" post="IgM and IgG ELISAs, RB IgG ELISA, as well"/>
  <result pre="IgM and IgG ELISAs, RB IgG ELISA, as well as" exact="Zika" post="and dengue NTs. For this comparison and based on"/>
  <result pre="For this comparison and based on the small number of" exact="Zika" post="patients in the YF group, all samples from pre-vaccinated"/>
  <result pre="displayed in Figs 10 and 11. Fig 10 Quantification of" exact="Zika" post="virus-specific IgM and IgG antibodies and broadly cross-reactive IgG"/>
  <result pre="and broadly cross-reactive IgG antibodies using single serum samples from" exact="Zika" post="cases. (A) Zika virus IgM ELISA units, (B) Zika"/>
  <result pre="IgG antibodies using single serum samples from Zika cases. (A)" exact="Zika" post="virus IgM ELISA units, (B) Zika virus IgG ELISA"/>
  <result pre="from Zika cases. (A) Zika virus IgM ELISA units, (B)" exact="Zika" post="virus IgG ELISA titers, and (C) Rio Bravo virus"/>
  <result pre="described in Methods. p-values are indicated in the graphs. ZIKV," exact="Zika" post="virus; RBV, Rio Bravo virus. Fig 11 Zika and"/>
  <result pre="graphs. ZIKV, Zika virus; RBV, Rio Bravo virus. Fig 11" exact="Zika" post="and dengue virus neutralization tests using single serum samples"/>
  <result pre="and dengue virus neutralization tests using single serum samples from" exact="Zika" post="cases. (A) Zika virus and (B) dengue virus NT50"/>
  <result pre="neutralization tests using single serum samples from Zika cases. (A)" exact="Zika" post="virus and (B) dengue virus NT50 titers from individual"/>
  <result pre="described in Methods. p-values are indicated in the graphs. ZIKV," exact="Zika" post="virus; DENV1, dengue virus serotype 1. The distribution of"/>
  <result pre="two groups was much more pronounced in IgG ELISAs with" exact="Zika" post="and RB antigens (Fig 10B and 10C), with a"/>
  <result pre="booster response of broadly flavivirus cross-reactive antibodies. The pattern of" exact="Zika" post="virus NT appeared very similar with samples of the"/>
  <result pre="prior TBE and/or YF vaccination on antibody responses to primary" exact="Zika" post="virus infections and observed a strong anamnestic response in"/>
  <result pre="lower (Fig 6A). Since the magnitude of the newly formed" exact="Zika" post="virus-specific IgG response was similar in naïve and pre-vaccinated"/>
  <result pre="Consistent with this picture, broadly cross-reactive antibodies did not neutralize" exact="Zika" post="and TBE viruses to a significant extent (Figs 6C"/>
  <result pre="the FL epitope [19, 21]. The different properties of infectious" exact="Zika" post="and dengue viruses with respect to the exposure of"/>
  <result pre="albeit at sub-neutralizing concentrations [30]. Broadly cross-reactive antibodies boostered by" exact="Zika" post="virus in the TBE and YF pre-vaccinated individuals only"/>
  <result pre="TBE and YF pre-vaccinated individuals only enhanced dengue but not" exact="Zika" post="virus in our in vitro assays, consistent with a"/>
  <result pre="neutralization and strong ADE by cross-reactive antibodies, in contrast to" exact="Zika" post="virus) may be biased by the specific properties of"/>
  <result pre="the FL [65]. In our analyses we used a stable" exact="Zika" post="virus E dimer (S4 Fig) which has a native"/>
  <result pre="sera accounted for a maximum of ~ 10% of total" exact="Zika" post="virus NT activity (S5 Fig). Although Zika virus was"/>
  <result pre="10% of total Zika virus NT activity (S5 Fig). Although" exact="Zika" post="virus was not enhanced by broadly flavivirus cross-reactive antibodies"/>
  <result pre="study, infection enhancement of this virus was readily demonstrable with" exact="Zika" post="virus-specific antibodies at sub-neutralizing concentrations, consistent with the generally"/>
  <result pre="IgM antibodies was recently shown in a mouse study with" exact="Zika" post="virus, demonstrating that IgG-mediated ADE can be weakened by"/>
  <result pre="of the total neutralizing activity in our samples of primary" exact="Zika" post="virus infections, with a tendency of a lower contribution"/>
  <result pre="clearance early after infection, also deduced from animal studies with" exact="West Nile" post="virus and IgM-deficient mice [24]. It appears that the"/>
  <result pre="the specific situations analyzed in our study, the impairment of" exact="Zika" post="virus-specific IgM responses was not very strong but demonstrated"/>
  <result pre="primary infection with a distantly related flavivirus, in this case" exact="Zika" post="virus. The modulation observed, albeit with relatively small groups"/>
  <result pre="here for additional data file. S2 Fig Control of the" exact="Zika" post="IgG avidity ELISA with early and late Zika virus"/>
  <result pre="of the Zika IgG avidity ELISA with early and late" exact="Zika" post="virus post-infection serum samples. (A) Serum collected 3 weeks"/>
  <result pre="here for additional data file. S3 Fig Controls for the" exact="Zika" post="IgM ELISA. (A) Standard curve of the positive control"/>
  <result pre="(B) results of 32 negative control sera in ELISA with" exact="Zika" post="virus E protein. The cut-off is shown as dotted"/>
  <result pre="for additional data file. S4 Fig Analysis of the recombinant" exact="Zika" post="virus E protein used in this study. (A) Rate"/>
  <result pre="used in this study. (A) Rate zonal ultracentrifugation of untreated" exact="Zika" post="virus E protein (red solid line), and after SDS-treatment"/>
  <result pre="positions of monomers and dimers, respectively. (B) Size-exclusion chromatograms of" exact="Zika" post="virus E (upper panel) and the monomeric WN virus"/>
  <result pre="the monomeric WN virus E (lower panel). (C) ELISA with" exact="Zika" post="virus E protein and EDE-specific monoclonal antibodies (C8 and"/>
  <result pre="Click here for additional data file. S5 Fig Results of" exact="Zika" post="virus neutralization of samples before and after antibody depletion"/>
  <result pre="neutralization of samples before and after antibody depletion with the" exact="Zika" post="virus E dimer. (A) Serum pools. (B) Individual serum"/>
  <result pre="the range. Colored columns: mock depletion (mock dep), empty columns:" exact="Zika" post="virus E depletion (ZIKV dep). n.t., not tested, because"/>
  <result pre="(TIF) LINK Click here for additional data file. S6 Fig" exact="Zika" post="virus IgG and IgM ELISA after IgG depletion of"/>
  <result pre="depleted with protein G columns as described in Methods. (A)" exact="Zika" post="virus IgG ELISA showing more than 99% depletion of"/>
  <result pre="IgG ELISA showing more than 99% depletion of IgG. (B)" exact="Zika" post="virus IgM ELISA to control for loss of IgM"/>
  <result pre="(TIF) LINK Click here for additional data file. S7 Fig" exact="Zika" post="virus IgM and IgG ELISA after IgM depletion of"/>
  <result pre="depleted with anti-IgM agarose beads as described in Methods. (A)" exact="Zika" post="virus IgM ELISA showing more than 99% depletion of"/>
  <result pre="IgM ELISA showing more than 99% depletion of IgM. (B)" exact="Zika" post="virus IgG ELISA to control for loss of IgG"/>
  <result pre="the World Health Organization. 201610.2471/BLT.16.171082. 3PiersonTC, DiamondMS. The emergence of" exact="Zika" post="virus and its new clinical syndromes. Nature. 2018;560(7720):573–81. 10.1038/s41586-018-0446-y30158602"/>
  <result pre="Virology. 2. 6 edPhiladelphia: Lippincott Williams &amp;amp; Wilkins; 2013. 5HalsteadSB." exact="Dengue" post="antibody-dependent enhancement: knowns and unknowns. Microbiology Spectrum. 2014;2(6). 10.1128/microbiolspec.AID-0022-201426104444"/>
  <result pre="population at risk of dengue. Nature Microbiology. 201910.1038/s41564-019-0476-831182801 10MussoD, GublerDJ." exact="Zika" post="virus. Clin Microbiol Rev. 2016;29(3):487–524. Epub 03/30. 10.1128/CMR.00072-15 .27029595"/>
  <result pre="GuzmanH, AraujoTP, XiaoSY. Immunization with heterologous flaviviruses protective against fatal" exact="West Nile" post="encephalitis. Emerg Infect Dis. 2002;8(3):245–51. 10.3201/eid0803.01023811927020 17BarzonL, PercivalleE, PacentiM,"/>
  <result pre="BravoP, et al.Virus and antibody dynamics in travelers with acute" exact="Zika" post="virus infection. Clin Infect Dis. 201710.1093/cid/cix967 .29300893 18HasanSS, SevvanaM,"/>
  <result pre="Dis. 201710.1093/cid/cix967 .29300893 18HasanSS, SevvanaM, KuhnRJ, RossmannMG. Structural biology of" exact="Zika" post="virus and other flaviviruses. Nat Struct Mol Biol. 2018;25(1):13–20."/>
  <result pre="KloseT, BudaG, SunL, et al.Refinement and analysis of the mature" exact="Zika" post="virus cryo-EM structure at 3.1 Å resolution. Structure. 2018;26(9):1169–77.e3."/>
  <result pre="A critical role for induced IgM in the protection against" exact="West Nile" post="virus infection. J Exp Med. 2003;198(12):1853–62. 10.1084/jem.2003122314662909 25LibratyDH, NisalakA,"/>
  <result pre="against tick-borne encephalitis. Vaccine. 2010;28(16):2827–31. 10.1016/j.vaccine.2010.02.00120167301 28StaplesJE, MonathTP, GershmanMD, BarrettADT." exact="Yellow fever" post="vaccines. In: OrensteinWA, OffitPA, EdwardsKM, editors. Plotkin's Vaccines (Seventh"/>
  <result pre="Plotkin's Vaccines (Seventh Edition): Elsevier; 2018 p. 1181–265.e20. 29RichnerJM, DiamondMS." exact="Zika" post="virus vaccines: immune response, current status, and future challenges."/>
  <result pre="FremontDH, et al.The stoichiometry of antibody-mediated neutralization and enhancement of" exact="West Nile" post="virus infection. Cell host &amp;amp; microbe. 2007;1(2):135–45. 10.1016/j.chom.2007.03.002 .18005691"/>
  <result pre="10.1089/08828240376363546512725690 32BardinaSV, BunducP, TripathiS, DuehrJ, FrereJJ, BrownJA, et al.Enhancement of" exact="Zika" post="virus pathogenesis by preexisting antiflavivirus immunity. Science. 201710.1126/science.aal4365 .28360135"/>
  <result pre="on the dominance of virus-specific CD4 T cell epitopes in" exact="Zika" post="virus infection. Front Immunol. 2018;9:119610.3389/fimmu.2018.0119629899743 38MandlCW, HeinzFX, KunzC. Sequence"/>
  <result pre="HeinzFX. Immunodominance and functional activities of antibody responses to inactivated" exact="West Nile" post="virus and recombinant subunit vaccines in mice. Journal of"/>
  <result pre="al.Development of a humanized monoclonal antibody with therapeutic potential against" exact="West Nile" post="virus. Nature medicine. 2005;11(5):522–30. Epub 04/24. 10.1038/nm1240 .15852016 63NybakkenGE,"/>
  <result pre=".15852016 63NybakkenGE, NelsonCA, ChenBR, DiamondMS, FremontDH. Crystal structure of the" exact="West Nile" post="virus envelope glycoprotein. J Virol. 2006;80(23):11467–74. 10.1128/JVI.01125-0616987985 64KanaiR, KarK,"/>
  <result pre="64KanaiR, KarK, AnthonyK, GouldLH, LedizetM, FikrigE, et al.Crystal structure of" exact="West Nile" post="virus envelope glycoprotein reveals viral surface epitopes. J Virol."/>
  <result pre="et al.Zika virus-immune plasmas from symptomatic and asymptomatic individuals enhance" exact="Zika" post="pathogenesis in adult and pregnant mice. mBio. 2019;10(4):e00758–19. 10.1128/mBio.00758-1931266863"/>
  <result pre="1983;158(1):258–63. 10.1084/jem.158.1.2586864163 69BalakrishnanT, Bela-OngDB, TohYX, FlamandM, DeviS, KohMB, et al." exact="Dengue" post="virus activates polyreactive, natural IgG B cells after primary"/>
 </snippets>
</snippetsTree>
